Canaccord Genuity Group Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price

Corcept Therapeutics (NASDAQ:CORT) had its price objective boosted by Canaccord Genuity Group from $99.00 to $100.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on the company. Wall Street Zen lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a report on Wednesday, December 31st. HC Wainwright boosted their price objective on shares of Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Finally, Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $83.50.

Corcept Therapeutics Stock Up 6.5%

Shares of NASDAQ:CORT opened at $43.98 on Friday. The firm has a 50 day simple moving average of $65.24 and a 200 day simple moving average of $71.10. Corcept Therapeutics has a 52 week low of $32.99 and a 52 week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. The company has a market cap of $4.63 billion, a PE ratio of 49.98 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). The firm had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The company’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 earnings per share. As a group, research analysts expect that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $73.65, for a total transaction of $368,250.00. Following the transaction, the insider directly owned 10,277 shares of the company’s stock, valued at $756,901.05. This represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the transaction, the insider owned 7,904 shares in the company, valued at approximately $628,526.08. This trade represents a 71.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 194,500 shares of company stock worth $14,186,410. Company insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Large investors have recently made changes to their positions in the stock. Pathstone Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after acquiring an additional 144 shares in the last quarter. Huntington National Bank grew its holdings in Corcept Therapeutics by 54.0% during the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 168 shares during the last quarter. Campbell Newman Asset Management Inc. raised its position in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock valued at $2,953,000 after purchasing an additional 170 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Corcept Therapeutics by 1.8% in the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after purchasing an additional 180 shares during the period. Finally, Clearstead Advisors LLC lifted its stake in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.